A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma
- Resource Type
- Article
- Source
- In
Clinical Lymphoma, Myeloma and Leukemia January 2019 19(1):29-34 - Subject
- Language
- ISSN
- 2152-2650